Vorinostat, a pan-HDAC inhibitor targeting class I and II histone deacetylases, is being developed for myeloproliferative neoplasms to address epigenetic dysregulation and inflammatory signaling. This evidence concerns the gene HDAC9 and myeloproliferative neoplasm.